A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.
Bristol Myers joins the legal fight over incoming Medicare drug price negotiations
Bristol Myers Squibb late last week joined Merck and the US Chamber of Commerce in challenging the Biden administration’s signature drug pricing reform — allowing,
June 21, 2023